Michael Ståhl

2.4k citations

63 papers · 1.6k indexed · h-index 20

Impact in

Endocrinology top 5%
- Legionella and Acanthamoeba research
Aging top 5%

Papers in

Oncology 30
- Colorectal Cancer Treatments and Studies 7
- Lung Cancer Research Studies 7
- Cancer Treatment and Pharmacology 6
- Cancer Diagnosis and Treatment 5
- Neutropenia and Cancer Infections 5
Endocrinology 3

Co-authors: Robbie Loewith Jürgen Beck Alexandre Huber Bernd Bodenmiller Ruedi Aebersold Yury Belyi Klaus Aktories Stefanie Wanka
Journals: Journal of Clinical Oncology (6 papers)Annals of Oncology (4 papers)European Journal of Pediatrics (3 papers)Journal of Biological Chemistry (2 papers)Clinical & Translational Oncology (1 paper)
Partner nations: Germany Switzerland United States

In The Last Decade

Michael Ståhl

59 papers receiving 1.6k citations

Peers

Countries citing papers authored by Michael Ståhl

Since Specialization

Citations

This map shows the geographic impact of Michael Ståhl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Ståhl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Ståhl more than expected).

Fields of papers citing papers by Michael Ståhl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Ståhl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Ståhl. The network helps show where Michael Ståhl may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael Ståhl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Ståhl Line = papers co-authored together Michael Ståhl links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Clinical & Translational Oncology ·Farah Baracat, Volker Heinemann, Laura Fischer, Frank Gieseler, Thomas Hoehler, Julia Mayerle, D. Quietzsch, Anke Reinacher‐Schick, Michael Schenk, G. Seipelt, Jens T. Siveke, Michael Ståhl, Ursula Vehling‐Kaiser, Dirk Waldschmidt, Klara Dorman, Danmei Zhang, C. Benedikt Westphalen, Michael von Bergwelt‐Baildon, Stefan Boeck, Michael Haas	2023	1
2	Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial Clinical Therapeutics ·Jason D. Lickliter, Ismael Kulmie, Emmanuelle Vincent, Armin Schueler, Christina Schürr, Corinne Seng Yue, Michael Ståhl, Martin Ullmann, Lian Fitriyani, Paul Griffin	2020	4
3	Decrease in plasma membrane tension triggers PtdIns(4,5)P2 phase separation to inactivate TORC2 Nature Cell Biology ·Margot Riggi, Jenifer E. Weiss, Nicolas Chiaruttini, Adai Colom, Beata Kuśmider, Vincent Mercier, Saeideh Soleimanpour, Michael Ståhl, Stefan Matile, Aurélien Roux, Robbie Loewith	2018	107
4	Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT) BMC Cancer ·Arndt Vogel, Yoshiyuki Tokuda, Álvaro Brasil Barbosa Neto, A. K. Shkvarok-Lisovenko, Alfredo Romano, Michael Ståhl	2016	24
5	Target of Rapamycin Complex 2 Regulates Actin Polarization and Endocytosis via Multiple Pathways Journal of Biological Chemistry ·Gabriel Pereira Fernandes, Bruno Andraus Filardi, Michael Ståhl, Stefania Vaga, Bernd Bodenmiller, Yann Abraham, Ireos Filipuzzi, N. Rao Movva, Ruedi Aebersold, Stephen B. Helliwell, Robbie Loewith	2015	66
6	TORC2 Signaling Pathway Guarantees Genome Stability in the Face of DNA Strand Breaks Molecular Cell ·Kenji Shimada, Ireos Filipuzzi, Michael Ståhl, Stephen B. Helliwell, Christian Studer, Dominic Hoepfner, Andrew Seeber, Robbie Loewith, N. Rao Movva, Susan M. Gasser	2013	66
7	Cancer Patients and the Internet: A Survey of the ‘Quality of Life’ Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie Onkologie ·Deniz Gencer, Alexandra Petryaeva, S Tei, Salah‐Eddin Al‐Batran, Michael Ståhl, Nan Zhang, Matthias Hipp, Gian Biattista Gazzola, Nicole Prasnikar, Tanja Trarbach, Christoph Stoll, Michael van Kampen, Andreas Hochhaus, Sylvie Lorenzen, Ralf‐Dieter Hofheinz	2011	7
8	Region of Elongation Factor 1A1 Involved in Substrate Recognition by Legionella pneumophila Glucosyltransferase Lgt1 Journal of Biological Chemistry ·Yury Belyi, Michael Ståhl, 崔永成, Peter Kaden, Burkhard Luy, Klaus Aktories	2009	32
9	Chaperone activation of the hepadnaviral reverse transcriptase for template RNA binding is established by the Hsp70 and stimulated by the Hsp90 system Nucleic Acids Research ·Michael Ståhl, Marco Retzlaff, Michael Nassal, Jürgen Beck	2007	52
10	Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junction Journal of Cancer Research and Clinical Oncology ·J. M. Rodríguez‐Menéndez, Michael Ståhl, Gisela Keller, Mario Sarbia	2006	9
11	Application of Adjuvant Chemotherapy in Colorectal Cancer – a Survey in the Region of Essen, Germany Oncology Research and Treatment ·Michael Ståhl, P. Duarte, Christian Müller, You Zhi-fang, H. Wilke	2004	0
12	In vitro gene delivery by a novel human calcitonin (hCT)-derived carrier peptide Bioorganic & Medicinal Chemistry Letters ·Ulrike Krauss, Martin Müller, Michael Ståhl, Annette G. Beck‐Sickinger	2003	35
13	Colorectal cancer and metastasectomy: treatment of advanced disease Annals of Oncology ·H. Wilke, Michael Ståhl	2000	12
14	Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: Long-term results of a phase II trial British Journal of Cancer ·Wilfried Eberhardt, Georgios Stamatis, Martin Stuschke, H. Wilke, Mark Müller, Iu. T. Tsukanov, Michael Flaßhove, J. Schütte, Michael Ståhl, L. Schlenger, Volker Budach, D Greschuchna, Georg Stüben, Helmut Teschler, H. Sack, S. Seeber	1999	71
15	Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro Anti-Cancer Drugs ·Michael Ståhl, Sabine Kasimir‐Bauer, A. Harstrick	1997	13
16	Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer Annals of Oncology ·Hans‐Joachim Wilke, U. Klaassen, W. Achterrath, Stephen P. Aubry, U. Vanhoefer, Alexandros Alexakos, A. Harstrick, Michael Ståhl, Wilfried Eberhardt, R. Becher, S. Seeber	1996	14
17	Liver glycogen synthase deficiency: A rarely diagnosed entity European Journal of Pediatrics ·R Gitzelmann, M. A. Spycher, Gerhard Feil, Joachim Müller, Shu Wenya, Michael Ståhl, N. U. Bosshard	1996	39
18	Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus Cancer Chemotherapy and Pharmacology ·A. Harstrick, Carsten Bokemeyer, P. Preusser, Alex Bittencourt Haas, Hans‐Joachim Meyer, Michael Ståhl, H. Knipp, Hans‐Joachim Schmoll, H. Wilke	1992	16
19	Folinic Acid (CF)/5-Fluorouracil (FUra) Combinations in Advanced Gastrointestinal Carcinomas Advances in experimental medicine and biology ·H. Wilke, Hans‐Joachim Schmoll, P. Preusser, U. Fink, Michael Ståhl, C. Schöber, H. Link, M. Freund, A.-R. Hanauske, 高広粂川, W. Achterrath, H. Poliwoda	1988	1
20	New seeds in old soil : study of the land reform process in Western Wollega, Ethiopia 1975-76 KTH Publication Database DiVA (KTH Royal Institute of Technology) ·Michael Ståhl	1977	26

About Michael Ståhl

Michael Ståhl is a scholar working on Oncology, Endocrinology, Cancer Research, Clinical Biochemistry and Pathology and Forensic Medicine, having authored 63 papers that have together received 1.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (7 papers), Lung Cancer Research Studies (7 papers), Cancer Treatment and Pharmacology (6 papers), Cancer Genomics and Diagnostics (5 papers), Neuroendocrine Tumor Research Advances (5 papers), Cancer Diagnosis and Treatment (5 papers), Neutropenia and Cancer Infections (5 papers) and Genetic factors in colorectal cancer (4 papers). The work is most often cited by research in Endocrinology (146 citations), Aging (42 citations), Molecular Biology (938 citations), Cell Biology (210 citations) and Oncology (278 citations). Michael Ståhl has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Robbie Loewith, Jürgen Beck, Alexandre Huber, Bernd Bodenmiller, Ruedi Aebersold, Yury Belyi, Klaus Aktories, Stefanie Wanka, Bertran Gerrits and Marco Retzlaff. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Pediatrics, Journal of Biological Chemistry and Clinical & Translational Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact